Keyes Stange & Wooten Wealth Management LLC Invests $200,000 in IQVIA Holdings Inc. (NYSE:IQV)

Keyes Stange & Wooten Wealth Management LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 844 shares of the medical research company’s stock, valued at approximately $200,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc grew its position in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in IQVIA during the second quarter worth about $27,000. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter worth about $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA during the 3rd quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA during the second quarter worth about $29,000. Institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

IQV has been the subject of several research analyst reports. Truist Financial dropped their target price on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research report on Monday, November 4th. The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Redburn Atlantic started coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Trading Up 2.1 %

IQV opened at $201.82 on Friday. The firm has a market capitalization of $36.63 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 2.03 and a beta of 1.51. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The business has a 50 day simple moving average of $222.67 and a two-hundred day simple moving average of $227.18. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.